Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Capoccia

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Stem Cells (Dayton, Ohio)|May 31, 2008
Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cellsIvana Rosová, Mo Dao, Ben Capoccia, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Immunodeficient mouse models to study human stem cell-mediated tissue repairPing Zhou, Sarah Hohm, Ben Capoccia, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Stem Cells (Dayton, Ohio)|May 31, 2008
Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cellsIvana Rosová, Mo Dao, Ben Capoccia, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Immunodeficient mouse models to study human stem cell-mediated tissue repairPing Zhou, Sarah Hohm, Ben Capoccia, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 1